目的 研究丁苯酞軟膠囊聯(lián)合依達(dá)拉奉注射液治療腦梗死的臨床療效。方法 選取2015年8月—2016年7月常德市第一人民醫(yī)院收治的腦梗死患者86例，按照治療方案不同分為對(duì)照組和治療組，每組各43例。對(duì)照組靜脈滴注依達(dá)拉奉注射液，30 mg加入到生理鹽水150 mL中，2次/d。治療組在對(duì)照組基礎(chǔ)上口服丁苯酞軟膠囊，0.2 g/次，3次/d。兩組患者均連續(xù)治療14 d。觀察兩組的臨床療效，比較兩組的血清神經(jīng)營養(yǎng)因子、炎癥反應(yīng)、神經(jīng)功能評(píng)分和日常生活能力（ADL）評(píng)分情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為74.42%、93.02%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組神經(jīng)元特異性烯醇化酶（NSE）水平顯著降低，神經(jīng)生長(zhǎng)因子（NGF）和腦源性神經(jīng)營養(yǎng)因子（BDNF）水平顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組白細(xì)胞介素-8（IL-8）、白細(xì)胞介素-10（IL-10）和C反應(yīng)蛋白（CRP）水平明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組這些觀察指標(biāo)的下降程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組神經(jīng)功能評(píng)分明顯降低，ADL評(píng)分明顯升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）。結(jié)論 丁苯酞軟膠囊聯(lián)合依達(dá)拉奉注射液治療腦梗死具有較好的臨床療效，能改善神經(jīng)功能和日常生活能力，調(diào)節(jié)血清神經(jīng)營養(yǎng)因子和炎癥反應(yīng)，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To study the effect of Butylphthalide Soft Capsules combined with Edaravone Injection in treatment of cerebral infarction. Methods Patients (86 cases) with cerebral infarction in the First People's Hospital of Changde from August 2015 to July 2016 were enrolled in this study. According to the difference treatment plan, patients were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were iv administered with Edaravone Injection, 30 mg added into normal saline 150 mL, twice daily. Patients in the treatment group were po administered with Butylphthalide Soft Capsules on the basis of the control group, 0.2 g/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, andserum neurotrophic factors, inflammatory response factors, neurological function scores, and ADL scores in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.42% and 93.02%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of NSE in two groups were significantly decreased, but the levels of NGF and BDNF in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of IL-8, IL-10, and CRP in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the neurological function scores in two groups were significantly decreased, but the ADL scores in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). The observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Butylphthalide Soft Capsules combined with Edaravone Injection has clinical curative effect in treatment of cerebral infarction, can improve neurological function and daily living ability, and regulate serum neurotrophic factors and inflammatory responses, with good safety, which has a certain clinical application value.